Dowsett, Mitch
Ellis, Matthew J. http://orcid.org/0000-0002-8467-8534
Dixon, J. Michael
Gluz, Oleg
Robertson, John
Kates, Ronald
Suman, Vera J.
Turnbull, Arran K.
Nitz, Ulrike
Christgen, Matthias
Kreipe, Hans
Kuemmel, Sherko
Bliss, Judith M.
Barry, Peter
Johnston, Stephen R.
Jacobs, Samuel A.
Ma, Cynthia X.
Smith, Ian E.
Harbeck, Nadia http://orcid.org/0000-0002-9744-7372
Funding for this research was provided by:
DH | National Institute for Health Research
Article History
Received: 28 April 2020
Accepted: 21 May 2020
First Online: 8 June 2020
Competing interests
: M.D. is on advisory board in Lilly, H3Biomedicine, AbbVie, Orion and consultancy: Radius; Honoraria for lectures: Nanostring, Myriad. M.J.E. reports ownership and income from Veracyte/Nanostring for Royalties for Prosigna and ad hoc consulting fees from Novartis, Pfizer, AstraZenica, GI therapeutics, Foundation Medicine, Sermonix, Abbvie. O.G. has Lecture/consultancy fees from Celgene, Roche, Genomic Health, Amgen, Pfizer, Novartis, Lilly, Nanostring, Eisai, MSD; assistance with travel costs: Celgene, Roche, Daiichi Sankyo; S.K. reports personal fees from Roche/Genentech, Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Somatex, MSD, Pfizer, Puma Biotechnology, PFM Medical, Lilly, Sonoscape. C.X.M. reports research funding from Pfizer, consulting fees from AstraZeneca, Novartis, Eli Lilly, Seattle Genetics, and Athenex Oncology. N.H. reports personal fees (lectures / consulting) from Agendia, Amgen, Astra Zeneca, BMS, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics. The remaining authors declare no conflict of interests.